The 2026 network meta-analysis compared many antibiotics at once through direct and indirect trial links and found antibiotic-alone treatment gives only mild, inconsistent benefit. Adults with persistent acne, acne continuing past age 25, should not read a high rank as proof it will work for them.
Lyu and colleagues advise limiting routine antibiotic-alone use, as reported in Clinical Drug Investigation the 2026 review. Superiority over placebo was not robust and global resistance remains a concern. That warning matters for long-standing adult disease, where average trial results can hide hormonal patterns and varied response.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the 2026 analysis actually test?
- Why does resistance matter for persistent acne?
- What do guidelines favor instead?
- How can you avoid overreading a ranking?
What did the 2026 analysis actually test?
Topical antibiotic monotherapy means an antibiotic cream or gel used alone, without benzoyl peroxide or a retinoid. Lyu and colleagues examined results across acne lesion types and found benefit was mild and inconsistent, with uncertain safety.
An earlier large analysis of mild-to-moderate acne reached a similar caution. Researchers in the British Journal of Dermatology found no convincing evidence that antibiotic-containing topicals, alone or combined, outperform non-antibiotic topicals.
Why does resistance matter for persistent acne?
Persistent adult acne mainly affects women over 25. The clinical guide in Anais Brasileiros de Dermatologia reports most adult female cases are persistent rather than late-onset and concentrate at ages 25-30.
A 2025 analysis in Frontiers in Microbiology tested 2,046 Cutibacterium acnes isolates. It estimated 22.4% resistance for clindamycin, 29.2% for erythromycin and over 43% for azithromycin and clarithromycin. Repeated solo use can therefore add selection pressure without clear gain.
What do guidelines favor instead?
The American Academy of Dermatology guideline strongly recommends topical benzoyl peroxide, retinoids and combinations for acne, as described in the 2024 guideline. It conditionally recommends clascoterone and other agents.
It also urges limiting systemic antibiotics and pairing them with benzoyl peroxide plus topicals. A 221-trial network analysis in Annals of Family Medicine found triple therapy with retinoid, benzoyl peroxide and antibiotic most effective after oral isotretinoin. That pattern favors short, paired use over long solo courses.
How can you avoid overreading a ranking?
A treatment ranked first may still have wide uncertainty or only trivial differences versus rivals. The BMJ methods review "Demystifying trial networks" warns readers to check effect sizes, heterogeneity and direct-versus-indirect inconsistency methods review.
For adults, that means treating rank as a starting clue, not a prescription: Bring your full treatment history, current combination products and prior antibiotic exposure to that visit. Ask your clinician if any antibiotic plan pairs it with benzoyl peroxide and sets a review date.
- Compare absolute change in lesions, not rank order alone
- Check who was studied and whether persistent or hormonal acne was included
- Ask whether the plan uses guideline-based combinations rather than solo antibiotics
- Set a review point for benefit, irritation and next steps
You Might Also Like
- Topical Acne Antibiotics and Resistance After the 2026 Meta-Analysis: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Limited Topical Spironolactone Evidence in the 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline